EWTX

SEC source: 0001655016-26-000001 · primarydocument.xml · nonDerivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,175

SEC source: 0002097992-25-000005 · primarydocument.xml · derivative · entry 1

Martin Christopher Nathan · CIK 0002097992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,150

Underlying: Common Stock · 45,150 shares

Expires 2035-11-19

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest each month beginning on December 19, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001853529-25-000007 · primarydocument.xml · derivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,147,365

Underlying: Common Stock · 100,000 shares

Expires 2032-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853529-25-000007 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,400

F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853529-25-000007 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001655016-25-000007 · primarydocument.xml · nonDerivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,702

F1 · price: The price reported in column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $18.55 to $18.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001705477-25-000005 · primarydocument.xml · derivative · entry 2

Nofi Michael · CIK 0001705477 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,500

Underlying: Common Stock · 262,500 shares

Expires 2035-11-10

F2 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on November 10, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001705477-25-000005 · primarydocument.xml · derivative · entry 1

Nofi Michael · CIK 0001705477 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,750

Underlying: Common Stock · 43,750 shares

Expires 2035-11-10

F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

SEC source: 0001655016-25-000004 · primarydocument.xml · nonDerivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,002

F1 · kind: Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the "Issuer") common stock, granted and released to the reporting person on October 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the Issuer's Outside Director Compensation Policy, as amended.

SEC source: 0001853529-25-000003 · primarydocument.xml · derivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,247,365

Underlying: Common Stock · 100,000 shares

Expires 2032-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853529-25-000003 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,400

F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.825, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853529-25-000003 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-005800 · primarydocument.xml · derivative · entry 2

Blaustein Robert · CIK 0002053149 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2035-08-12

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005800 · primarydocument.xml · derivative · entry 1

Blaustein Robert · CIK 0002053149 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-08-12

F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 5

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,750

Underlying: Common Stock · 168,750 shares

Expires 2035-08-12

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 28,125 shares

Expires 2035-08-12

F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,344

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005796 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,400

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005796 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,005 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 5

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2035-08-12

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 4

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-08-12

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 3

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,344

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005798 · primarydocument.xml · nonDerivative · entry 2

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,645

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005798 · primarydocument.xml · nonDerivative · entry 1

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-005797 · primarydocument.xml · derivative · entry 5

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,250

Underlying: Common Stock · 161,250 shares

Expires 2035-08-12

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005797 · primarydocument.xml · derivative · entry 4

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,875

Underlying: Common Stock · 26,875 shares

Expires 2035-08-12

F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005797 · primarydocument.xml · derivative · entry 3

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,344

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005797 · primarydocument.xml · nonDerivative · entry 2

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,162

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005797 · primarydocument.xml · nonDerivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 795 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 5

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,250

Underlying: Common Stock · 161,250 shares

Expires 2035-08-12

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 4

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,875

Underlying: Common Stock · 26,875 shares

Expires 2035-08-12

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,344

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005799 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,214

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005799 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 9

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 525,000

Underlying: Common Stock · 525,000 shares

Expires 2035-08-12

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 8

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2035-08-12

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 7

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,907

Underlying: Common Stock · 17,968 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005795 · primarydocument.xml · nonDerivative · entry 2

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,615

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005795 · primarydocument.xml · nonDerivative · entry 1

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 5

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,750

Underlying: Common Stock · 168,750 shares

Expires 2035-08-12

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 4

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 28,125 shares

Expires 2035-08-12

F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 3

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,344

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001562180-25-005794 · primarydocument.xml · nonDerivative · entry 2

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,361

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-25-005794 · primarydocument.xml · nonDerivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 854 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-25-005233 · primarydocument.xml · nonDerivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,274

F1 · kind: Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the "Issuer") common stock, granted and released to the reporting person on July 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the the Issuer's Outside Director Compensation Policy, as amended.

SEC source: 0001562180-25-004961 · primarydocument.xml · derivative · entry 1

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

SEC source: 0001562180-25-004960 · primarydocument.xml · derivative · entry 1

Edris Badreddin · CIK 0001786966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

SEC source: 0001562180-25-004959 · primarydocument.xml · derivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

SEC source: 0001562180-25-004958 · primarydocument.xml · derivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

SEC source: 0001562180-25-004957 · primarydocument.xml · derivative · entry 1

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-16

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.